A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Trial Profile

A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Zolmitriptan (Primary) ; Zolmitriptan; Zolmitriptan
  • Indications Migraine
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 09 Jun 2016 According to an Acorda Therapeutics media release, results (n=21) of this trial were presented at the 58th Annual Scientific Meeting of the American Headache Society, 2016.
    • 09 Jun 2016 Results (n=21) published in an Acorda Therapeutics media release.
    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top